3Aseptic processing and sterility assurance
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm failed to adequately investigate out-of-limit 100% visual inspection findings for two batches of sterile ophthalmic drug products that exceeded the (b)(4) % total reject limit. Rather than conducting a full 100% re-inspection, only (b)(4) units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles. Both batches were released and shipped to the U.S. market without determining whether the particles were intrinsic, extrinsic, or inherent. Ophthalmic products operations should be designed to prevent particle contamination and to protect consumers from the risk of instilling potentially harmful particles into the eye. In addition, when categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Microbes introduced directly into the eye can pose a serious risk to consumers. Irreversible damage, including partial vision loss or blindness, can occur and, in some cases, may progress to life-threatening systemic infection. In your response, you acknowledge that your investigations were inadequate and that samples sent to an external laboratory for Fourier-Transform Infrared spectroscopic analysis could not conclusively determine the composition or source of the particles. While you identified a statistical correlation between high reject rates lots and a specific (b)(4) container supplier, the particle source(s) was not confirmed through analytical testing. Your response is inadequate. The identification of particles and their sources remained inconclusive and incomplete at the time of your initial response. Your response also did not address your decision to release batches despite your significant adverse quality defect trends. A substantial number of consumer complaints have been received since 2019, including reports of leakage, burning and stinging sensation, worsening eye redness, blurry vision, and reports of foreign matter or “floating matter.” Your firm recorded "no need" or “NA” for corrective action for those customer complaints. In response to this letter, provide: A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted. A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following: o Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products. o Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates historically found in your operation. o Conducting rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products. o Implementing destructive testing and other advanced technologies (e.g., (b)(4) ) as appropriate, with statistically significant sample sizes, for drug products that are difficult to inspect (e.g., (b)(4) containers). o Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall/complaint data, and quality risk management to improve the visual inspection program. o Remediating your visual inspection program, including establishing new written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant. The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of the product labeling, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” (collectively, “ROHTO® Cooling Eye Drops products”) are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including your website and social media, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: All ROHTO® Cooling Eye Drops products ““Our cooling eye drops additionally strengthen eye’s lipid film, promoting better stability of the tear film…” [from your “About” webpage, https://rohtoeyedrops.com/pages/about] “ROHTO® Cooling Eye Drops COOL RELIEF” “ROHTO® Cooling Eye Drops COOL RELIEF . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes….” [from product label] “ROHTO® Cooling Eye Drops ALL-IN-ONE” “ROHTO® Cooling Eye Drops ALL-IN-ONE . . . Drug Facts . . . Purpose…Lubricant…Redness Reliever…Astringent . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label] “ROHTO® Cooling Eye Drops MAX STRENGTH” “ROHTO® Cooling Eye Drops MAX STRENGTH . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label] “ROHTO® Cooling Eye Drops DIGI EYE” “ROHTO® Cooling Eye Drops DIGI EYE . . . Drug Facts . . Purpose…Lubricant…Redness reliever . . . soothes up to 8 hrs. . . . Proprietary formula cools…eyes. . . . Soothes Redness and Dryness due to Digital Eye Strain…” [from product label] “…specially designed to provide eye strain relief from the symptoms of Digital Eye Strain.” [from product webpage, https://rohtoeyedrops.com/products/rohto-digi-eye-digital-eye-strain-eye-drops] “ROHTO® Cooling Eye Drops OPTIC GLOW” “ROHTO® Cooling Eye Drops OPTIC GLOW . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . Soothes up to 8 hrs. . . . Proprietary formula cools…eyes…” [from product label] “Helps improve the health of the corneal surface….” [from product webpage, https://rohtoeyedrops.com/products/rohto-eye-drops-optic-glow-eye-whitening-drops] “ROHTO® Cooling Eye Drops DRY AID” “ROHTO® Cooling Eye Drops DRY AID . . . Drug Facts . . . Purpose…Lubricant . . . Soothes up to 12 hrs. Long-Lasting . . . Repairs Natural Tear Film . . . Proprietary formula cools…eyes. . . . Repairs All Layers Of The Tear Film…” [from product label] “Rohto® Dry Aid® Eye Drops For Dry Eyes with Liquid Shield™ Technology . . . repairs the natural tear film over time . . . Unlike most over-the-counter eye drops that only work on one layer of the tear film, Rohto® Dry Aid® with Liquid Shield™ Technology works in a unique way to restore moisture to the tear film by working on all layers to mimic a stable, natural tear.” [from product webpage, https://rohtoeyedrops.com/products/rohto-dry-aid-eye-drops-for-dry-eyes] “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF . . . Drug Facts . . . Purpose…Lubricant . . . Our eye drops…relieve symptoms of digital eye strain . . . protect your corneal cells from UV and Blue Light damage . . . HydroCorneal™ Protection Technology” [from product webpage, https://rohtoeyedrops.com/products/rohto-dual-light-relief-hydrating-eye-drops] “ROHTO® Dual Light Relief . . . It employs HydroCorneal™ protection technology to protect corneal cells from UV damage.” [from your @rohtoeyedrops Instagram post, https://www.instagram.com/p/DQb_GmTAD7c/] Based on the above labeling evidence, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are intended for use as ophthalmic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d). A drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as "OTC monograph drugs"—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your ROHTO® Cooling Eye Drops products, in order to be GRASE and not new drugs the products must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (henceforth “M018”). 1 However, your nonprescription ROHTO® Cooling Eye Drops ophthalmic drug products do not conform to the conditions specified in M018 for the reasons described below. Claims on the product labeling for your ROHTO® Cooling Eye Drops products include intended uses that are not permitted in M018 for ophthalmic drug products. Specifically, the names of all of your ROHTO® Cooling Eye Drops products contain the term “Cooling.” Also, the “About” webpage of your website states that your ROHTO® Cooling Eye Drops products “strengthen eye’s lipid film, promoting better stability of the tear film.” In addition, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” product labels state that the product “cools eyes” and reference, “CoolSense™ Technology.” Such claims go beyond the allowed general intended uses for OTC ophthalmic drug products and do not conform to M018. Furthermore, your products “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” include additional intended uses that are not permitted in M018. For example, your product label for “ROHTO® Cooling Eye Drops DIGI EYE” states, “Soothes Redness and Dryness due to Digital Eye Strain,” and your website states that this product is “designed to provide eye strain relief from the symptoms of Digital Eye Strain.” Additionally, your website states that the product “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” is intended to “…relieve symptoms of digital eye strain,” and “protect your corneal cells from UV and Blue Light damage.” Moreover, a post on your @rohtoeyedrops Instagram page states that this product “employs HydroCorneal™ protection technology to protect corneal cells from UV damage. In addition, your website states that the product, “ROHTO® Cooling Eye Drops OPTIC GLOW” “helps improve the health of the corneal surface….” Such claims go beyond the allowed general intended uses for ophthalmic drug products and do not conform to M018. The product labels for “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” claim that these products “soothes up to 8 hrs.” and your product label for “ROHTO® Cooling Eye Drops DRY AID” claims that it “Soothes up to 12 hrs.” Time-specific extended efficacy claims such as these do not conform to M018. Thus, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” products do not comply with the applicable conditions specified in M018 and have not otherwise been found to be GRASE. 2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). Misbranded Drug Violations Your ROHTO® Cooling Eye Drops products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the product labeling include statements that misleadingly suggest that the drug products are endorsed by FDA and are cGMP compliant. Specifically, on your “About” webpage, you display the acronym “FDA,” in a form that is similar to the FDA logo. Your use of the acronym FDA in a form that is similar to the FDA logo on your website misleadingly suggests that the drug products are approved or endorsed by FDA in some way. Your ROHTO® Cooling Eye Drops products are not the subject of an FDA-approved application. Additionally, on your website you claim, “Our manufacturing practices are US FDA GMP Compliant…,” and “GMP Compliance guarantees our eye drops are 100% sterile, 100% free from contamination, and meet rigorous quality standards….” Generally, current good manufacturing practice (CGMP) compliance cannot be implied or explicitly indicated on product labeling. Based solely on a determination of CGMP compliance at one point in time it would be unreasonable to assure permanent CGMP compliance, or to guarantee that products are 100% sterile or free from contamination at any given time. Moreover, when even a single aspect of a firm’s operations deviates from CGMP during the course of manufacturing a product, regardless of the significance of the deficiency, the product is deemed adulterated under section 501(a)(2)(B) of the FD&C Act. Your firm cannot reliably guarantee that a product is sterile, free from contamination, or meets rigorous quality standards when it manufactures that product under conditions that fail to meet CGMP requirements, as described above. Such representation can mislead consumers into believing the product is safe despite the existence of serious manufacturing risks. Therefore, these products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because your labeling representation suggesting that your products are FDA-approved and CGMP compliant is false or misleading. Additionally, your ROHTO® Cooling Eye Drops products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Data Integrity Remediation Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https://www.fda.gov/media/119267/download. We strongly recommend that you retain an independent, qualified third-party consultant to assist in your remediation. In response to this letter, provide: A comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include: o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude. o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party. o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies. o A comprehensive retrospective evaluation of the nature of the testing/manufacturing/other data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include: o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA. o A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm. o Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring. o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data. o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol. o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed). o A status report for any of the above activities already underway or completed. Drug Recall On July 7, 2026, FDA held a teleconference with you recommending you recall all drug batches from the U.S. market. On July 8, 2026, you agreed to voluntary recall all drugs in current distribution in the United States. On July 14, 2026, you initiated a voluntary recall of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance. The recalls were posted to the FDA’s Enforcement Report website at: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221557 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221558 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221559 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221560 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221561 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221562 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221563 https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221564 Drug Production Suspended We acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future. If you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA). CGMP Consultant Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit 3 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.